loading page

Prime Editing in vivo: Correcting the Leptin Receptor of db/db Mice
  • +7
  • Kyung Lee,
  • Yanping Xu,
  • Bingchuan Geng,
  • Jongsoo Kim,
  • Natalie Kellon,
  • Michele He,
  • Zhentao Zhang,
  • Deqiang Li,
  • Doug Gouchoe,
  • Hua Zhu
Kyung Lee
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Yanping Xu
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute

Corresponding Author:[email protected]

Author Profile
Bingchuan Geng
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Jongsoo Kim
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Natalie Kellon
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Michele He
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Zhentao Zhang
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile
Deqiang Li
Nationwide Children’s Hospital
Author Profile
Doug Gouchoe
The Ohio State University Wexner Medical Center
Author Profile
Hua Zhu
The Ohio State University Wexner Medical Center Dorothy M Davis Heart and Lung Research Institute
Author Profile

Abstract

Genetic diseases can be caused by monogenic diseases, which result from a single gene mutation in the DNA sequence. Many innovative approaches have been developed to cure monogenic genetic diseases, namely by genome editing. A specific type of genomic editing, prime editing, has the potential advantage to edit the human genome without requiring double-strand breaks or donor DNA templates for editing. Additionally, prime editing does not require a precisely positioned protospacer adjacent motif (PAM) sequence, which offers flexible target and more precise genomic editing. Here we detail a novel construction of a prime editing extended guide RNA (pegRNA) to target mutated leptin receptors in B6.BKS(D)-Leprdb/J mice (db/db mice). The pegRNA was then injected into the flexor digitorum brevis (FDB) muscle of db/db mice to demonstrate in vivo efficacy, which resulted in pegRNA mediated base transversion at endogenous base transversion. Genomic DNA sequencing confirmed that prime editing could correct the mutation of leptin receptor gene in db/db mice. Furthermore, prime editing treated skeletal muscle exhibited enhanced leptin receptor signals. Thus, the current study showed in vivo efficacy of prime editing to correct mutant protein and rescue the physiology associated with functional protein.
23 Mar 2024Submission Checks Completed
23 Mar 2024Assigned to Editor
23 Mar 2024Review(s) Completed, Editorial Evaluation Pending
23 Mar 2024Reviewer(s) Assigned